Education
About Us
Working with TipRanks
Follow Us
Dr. Reddy's Laboratories Ltd (RDY)
NYSE:RDY
Earnings Data
Report Date
May 08, 2026Before Open (Confirmed)
Period Ending
2026 (Q4)Consensus EPS Forecast
0.15Last Year’s EPS
0.22Same Quarter Last Year
Based on 0 Analysts Ratings
Earnings Call Summary
Earnings Call Sentiment|Positive
The call reflects a mixed but overall constructive picture: the company demonstrated resilient top-line growth (+4.4% YoY) driven by strong performance in India and emerging markets (double-digit growth) and meaningful pipeline and commercial milestones (semaglutide authorization in India, abatacept filings, European denosumab approval). Liquidity remains healthy (net cash surplus ~USD 342m) and integration of acquisitions is progressing. Offsetting these positives are margin compression, profit declines, continued U.S. generics weakness due to Lenalidomide decline, regulatory/inspection-related delays for some biosimilars (denosumab, rituximab) and elevated SG&A driven by strategic investments and a one-time labor-code provision. On balance the positive operational momentum, pipeline progress and strong cash position modestly outweigh the near-term margin and regulatory challenges.Company Guidance
Revenue Growth and Base Business Momentum
Consolidated Q3 FY'26 revenue INR 8,727 crores (USD 971m), up 4.4% YoY (down 0.9% QoQ). Underlying base business excluding Lenalidomide delivered double-digit growth, aided by favorable forex.
Strong India and Emerging Markets Performance
India revenue INR 1,603 crores, +19% YoY (+2% QoQ); organic India growth ~17-18% excluding Stugeron. Emerging markets revenue INR 1,896 crores, +32% YoY and +15% QoQ; Russia grew ~21% YoY (constant currency). India outperformed IPM (MQT 12.3% vs IPM 11.8%; MAT 9.7% vs IPM 8.9%).
Pipeline and Strategic Regulatory Progress
Key regulatory and pipeline milestones: semaglutide injection received marketing authorization in India and local manufacturing license (India launch planned Mar 21); semaglutide filings underway across emerging markets and response submitted to Health Canada (goal date by May). Abatacept IV BLA filed (Dec 2025) and subcutaneous filing planned Jul 2026; European launch plans for abatacept targeted around Jul 2027.
Biologics and Biosimilars Approvals / Launches in Europe
Denosumab biosimilar received CHMP positive opinion and European Commission approval; MHRA (UK) approval received and product launched in Germany with preparations for U.K. and other European launches.
Cash Generation and Strong Liquidity
Free cash flow for the quarter INR 374 crores (USD 42m); capex INR 669 crores (USD 75m). Net cash surplus INR 3,069 crores (USD 342m) as of Dec 31, 2025. Active FX hedges: USD 481m hedged at INR 89.1–90.3 and RUB 2.93bn at fixed rate.
Commercial Execution and New Product Launches
Launched 30 new products across emerging markets, 10 new generics in Europe, 6 new products in North America during the quarter, and introduced 2 new brands in India; 31 Drug Master Files filed globally and 28 global generic filings completed.
Acquisition Integration and Consumer Health
Integration of acquired Nicotine Replacement Therapy (NRT) business progressing per plan with ~85% of business by value under operational control; NRT delivered overall reported growth (~25% YoY) with constant currency growth ~8% YoY and EBITDA at or above targeted ~25% range.
Sustainability and CDMO/Innovation Progress
Committed to a science-based net-zero target by FY2045 (first Indian pharma with such a commitment) and leadership in CDP Water Security & Climate categories; Aurigene (APSL) served as exclusive API manufacturer for 2 novel USFDA-approved drugs in 2025 and delivered 3 discovery programs via Aurigene.Ai.
RDY Earnings History
The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.
Beat
Missed
RDY Earnings-Related Price Changes
Report Date | Price 1 Day Before | Price 1 Day After | Percentage Change |
|---|---|---|---|
Jan 27, 2026 | $13.78 | $13.71 | -0.51% |
Oct 24, 2025 | $14.62 | $14.58 | -0.27% |
Jul 29, 2025 | $14.70 | $14.76 | +0.41% |
May 09, 2025 | $13.11 | $13.33 | +1.67% |
Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.
FAQ
When does Dr. Reddy's Laboratories Ltd (RDY) report earnings?
Dr. Reddy's Laboratories Ltd (RDY) is schdueled to report earning on May 08, 2026, Before Open (Confirmed).
What is Dr. Reddy's Laboratories Ltd (RDY) earnings time?
Dr. Reddy's Laboratories Ltd (RDY) earnings time is at May 08, 2026, Before Open (Confirmed).
Where can I see when companies are reporting earnings?
You can see which companies are reporting today on our designated earnings calendar.
What companies are reporting earnings today?
You can see a list of the companies which are reporting today on TipRanks earnings calendar.
What is RDY EPS forecast?
RDY EPS forecast for the fiscal quarter 2026 (Q4) is 0.15.